For biogenerics, to a greater extent than for branded biopharmaceuticals, squeezing every possible basis point out of the COGS line will be consequential. That’s what makes GTC an excellent fit for the FoB arena in spite of the improvements that have been realized and will continue to be realized in cell-culture yields.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.